bioMerieux (FR:BIM) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
bioMérieux has announced FDA 510(k) clearance for its VITEK® REVEAL™ antibiogram system, which provides rapid antibiotic sensitivity tests crucial for treating sepsis and combating antibiotic resistance. This innovative technology delivers results from positive blood cultures within approximately 5.5 to 6 hours, enabling same-day therapeutic decisions. The clearance marks a significant milestone for bioMérieux, enhancing its comprehensive solutions in the diagnostics market and supporting the proper use of antibiotics.
For further insights into FR:BIM stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue